




- (51) **International Patent Classification:**
C07D 213/53 (2006.01) *A61P 35/00* (2006.01)
A61K 31/444 (2006.01)
- (21) **International Application Number:**
PCT/AU2011/001631
- (22) **International Filing Date:**
16 December 2011 (16.12.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
2010905539 17 December 2010 (17.12.2010) AU
- (72) **Inventors; and**
- (71) **Applicants :** RICHARDSON, Des R [AU/AU]; 1213 Pioneer Drive, Carnes Hill, Sydney, NSW 2171 (AU).
LOVEJOY, David B [AU/AU]; 55/32-42 Rosehill Street, Redfern, NSW 2016 (AU).
- (74) **Agent:** ALLENS ARTHUR ROBINSON; Patent & Trade Marks Attorneys, Deutsche Bank Place, Corner Hunter & Phillip Streets, Sydney, NSW 2000 (AU).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** THIOSEMICARBAZONE COMPOUNDS AND USE IN THE TREATMENT OF CANCER



(57) **Abstract:** The present invention relates to dipyriddy thiosemicarbazone compounds of formula (I): wherein R¹ is cyclohexyl or ethyl; as well as pharmaceutical compositions containing those compounds, and the use of those compounds and compositions in the treatment of cancer.

Thiosemicarbazone compounds and use in the treatment of cancer

[001] This application claims priority from Australian Provisional Patent Application No 2010905539 filed 17 December 2010, the entire contents of which are hereby incorporated by cross-reference.

Technical Field

[002] The present invention relates to thiosemicarbazone compounds and their use in therapy. More particularly, the invention relates to a selection of dipyridyl thiosemicarbazone compounds, pharmaceutical compositions containing those compounds, and the use of those compounds and compositions in the treatment of cancer.

Background Art

[003] Thiosemicarbazone iron chelators are a class of anti-cancer agents that have been found to be extremely potent and selective against a number of different neoplasms both *in vitro* and *in vivo*. These compounds function by targeting iron, an essential element for DNA synthesis, in cancer cells. Iron chelators were initially developed for iron-overload diseases such as β -thalassemia, with the chelator desferrioxamine (*DFO*) being the most widely used treatment for this disease. However, clinical trials examining DFO against neuroblastoma found that this agent was effective at inhibiting the progression of this cancer in some patients. These early studies were the first to identify the potential of iron chelators as anti-cancer agents. Since then, iron chelators designed specifically for the treatment of cancer have been developed, with the thiosemicarbazone iron chelator 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (*Triapine*[®]) (Vion Pharmaceuticals, New Haven CT, United States of America) entering a number of phase I and II clinical trials.

[004] Thiosemicarbazone iron chelators function by binding iron and copper and forming redox-active complexes, leading to the production of reactive oxygen species (ROS) that induce cancer cell cytotoxicity. One of the most active compounds developed to date is a thiosemicarbazone class of iron chelator, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone, (abbreviated herein as *Dp44mT*), which is described in WO 2004/069801. *Dp44mT* has been demonstrated to markedly and significantly reduce the growth of a number of different tumors *in vitro* and *in vivo* and was found to be more potent and less toxic than *Triapine*[®]. However, studies using high, non-optimal doses of *Dp44mT* found that it induced some cardiotoxicity in nude mice.


[005] Thiosemicarbazone compounds target the metastasis suppressor, NDRG1. NDRG1 inhibits both growth and metastasis as well as angiogenesis of pancreatic cancer *in vivo* leading to reduced tumor progression. Moreover, NDRG1 has also recently been correlated with increased differentiation of pancreatic cancers and its potential as a promising therapeutic target

against pancreatic cancer has been reported (eg, Kovacevic, Z. and D. R. Richardson (2006). *Carcinogenesis* **27**: 2355-66; Maruyama, Y., M. Ono, et al. (2006). *Cancer Res* **66**: 6233-42). NDRG1 has a number of key molecular targets in pancreatic cancer including the tumor suppressors PTEN and SMAD4, both of which are up-regulated in response to NDRG1. Therefore, NDRG1 may be a promising therapeutic target, especially for the treatment of pancreatic cancer. NDRG1 was recently found to be up-regulated using iron-chelating anti-cancer agents *in vitro* and *in vivo*. Iron chelators increased NDRG1 expression via hypoxia-inducible transcription factor (HIF-1)-dependent mechanisms, although HIF-1-independent pathways have also been observed. Iron-chelating anti-cancer agents therefore provide an important opportunity to target NDRG1 expression in cancer cells by cellular iron depletion.

[006] There is a need for new and alternative treatments for cancer. The present invention is directed to a selection of thiosemicarbazone compounds that advantageously inhibit cellular proliferation and may be useful for the treatment of cancer.

Summary of Invention

[007] In one aspect, the present invention relates to thiosemicarbazone compounds of general formula (I):



wherein R¹ is cyclohexyl or ethyl;

and salts, hydrates and solvates thereof.

[008] In a preferred embodiment the invention relates to the compound di-2-pyridylketone 4-ethyl-4-methyl-3-thiosemicarbazone (abbreviated herein as **Dp4e4mT**) and salts, hydrates and solvates thereof.

[009] In another preferred embodiment the invention relates to the compound di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (abbreviated herein as **Dp4cycH4mT**), salts, hydrates and solvates thereof.

[010] In preferred embodiments the salts are pharmaceutically acceptable salts. Acid addition salts, such as hydrochloride salts, are a particularly preferred embodiment of the invention.

[011] In another aspect the invention relates to a pharmaceutical composition comprising a compound of formula (I), or a salt, hydrate or solvate thereof, together with a pharmaceutically acceptable excipient, diluent or adjuvant.

[012] In a further aspect the present invention relates to a method of treating cancer in a mammal, the method comprising administering to a mammal in need thereof an effective amount of a compound of formula (I) or a salt, hydrate or solvate thereof, or a pharmaceutical composition thereof. In preferred embodiments the mammal is a human.

[013] In another aspect the present invention relates to the use of a compound of formula (I) or a salt, hydrate or solvate thereof in the manufacture of a medicament for the treatment of cancer.

[014] In a further embodiment the invention relates to a compound of formula (I) or a salt, hydrate or solvate thereof, or a pharmaceutical composition thereof, for the treatment of cancer.

[015] The compounds of the invention are useful for the treatment of a wide variety of cancers, including solid and non-solid tumours, including but not limited to, melanoma, skin cancer, breast cancer, prostate cancer, bladder cancer, liver cancer, gastrointestinal cancer, colon and rectal cancer, brain tumour, head and neck cancer, bone cancer, pancreatic cancer, uterine cancer, ovarian cancer, cervical cancer, lung cancer as well as haematological tumours (eg, leukaemias and lymphomas). In preferred embodiments the cancer is selected from pancreatic cancer, lung cancer, and brain tumours. In particularly preferred embodiments the cancer is pancreatic cancer. In other particularly preferred embodiments the cancer is lung cancer. In other preferred embodiments the cancer is brain tumour. In preferred embodiments the compounds of the invention are useful for the treatment of solid tumours. In other preferred embodiments the compounds of the invention are useful for the treatment of non-solid tumours.

[016] Other embodiments of the invention disclosed herein are directed to a method of inhibiting cellular proliferation, the method comprising contacting one or more cells with an effective amount of a compound of formula (I) or a salt, hydrate or solvate thereof. The cells may be *in vitro* or *in vivo*. Preferably the cells are mammalian cells.

[017] Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps. Thus, in the context of this specification, the term 'comprising' means 'including principally, but not necessarily solely'.

[018] Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention, in Australia or elsewhere, before the priority date of each claim of this specification.

Brief Description of the Drawings

[019] **Figure 1. A** Structural formulae of the compounds Dp4e4mT and Dp4cycH4mT. **B** General synthetic scheme for Dp4cycH4mT

- [020] **Figure 2.** Antiproliferative activity of Dp4e4mT and Dp4cycH4mT against SK-N-MC neuroepithelioma.
- [021] **Figure 3.** Anti-proliferative activity of Dp4cycH4mT against pancreatic cancer cell lines.
- [022] **Figure 4.** Iron efflux (A) and iron uptake (B) studies in SK-N-MC neuroepithelioma cells.
- [023] **Figure 5.** Growth of DMS-53 lung carcinoma in nude mice. Dp4e4mT i.v administration study.
- [024] **Figure 6.** Growth of DMS-53 lung carcinoma in nude mice. Dp4e4mT i.v administration study: assessment of cardiac fibrosis.
- [025] **Figure 7.** Growth of DMS-53 lung carcinoma in nude mice. Dp4e4mT oral administration study: **A.** Tumour size v days of treatment. **B.** Tumour weight.
- [026] **Figure 8.** DMS-53 lung carcinoma in nude mice. Dp4e4mT oral administration study: Histological analysis of heart, spleen, liver.
- [027] **Figure 9.** Growth of PANC 1 pancreatic carcinoma in nude mice. Dp4cycH4mT i.v administration study: **A.** Tumour size v days of treatment. **B.** Tumour weight. **C.** Photographs of representative tumours.
- [028] **Figure 10.** Growth of PANC 1 pancreatic carcinoma in nude mice. Dp4cycH4mT i.v administration study: Histological analysis of heart, spleen, liver.
- [029] **Figure 11.** Growth of PANC 1 pancreatic carcinoma in nude mice. Dp4cycH4mT i.v administration study: effect of Dp4cycH4mT on NDRG-1, TfR and cell cycle molecules.
- [030] **Figure 12.** Effect of DFO and thiosemicarbazone chelators on methHb-formation *in vitro*. Whole RBCs were incubated with 1-25 μ M chelator at 37 °C for 3 h. Cells were lysed with ultra-pure H₂O and methHb levels were measured spectrophotometrically. Results are the mean \pm SD from 3 experiments.
- [031] **Figure 13.** Effect of thiosemicarbazone chelators on methHb-formation *in vivo*. MethHb after Dp44mT, Triapine[®] or Dp4cycH4mT treatment *in vivo* at a dose of 6 mg/kg administered intravenously *via* the tail vein. Mice in the control group were treated with vehicle alone. At 30 minutes post-administration, whole blood was collected for determination of methHb levels.
- [032] **Figure 14.** Effect of thiosemicarbazone chelators on metMb-formation *in vivo*. MetMb levels after Dp44mT Triapine[®] or Dp4cycH4mT treatment *in vivo* at a dose of 6 mg/kg administered intravenously *via* the tail vein. Mice in the control group were treated with vehicle alone. At 30 min post-administration, whole hearts were collected for determination of metMb levels.

Definitions

[033] The following are some definitions that may be helpful in understanding the description of the present invention. These are intended as general definitions and should in no way limit the scope of the present invention to those terms alone, but are put forth for a better understanding of the following description.

[034] Unless the context requires otherwise or specifically stated to the contrary, integers, steps, or elements of the invention recited herein as singular integers, steps or elements clearly encompass both singular and plural forms of the recited integers, steps or elements.

[035] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps, features, compositions and compounds.

[036] The compounds of formula (I) are tridentate ligands capable of chelating transition metal ions, such as iron (Fe(II) and Fe(III)). Accordingly, throughout this specification the compounds of the invention may be referred to as 'ligands', 'chelators' or 'iron chelators'. Throughout this specification, a reference to 'compound(s)' or 'chelators' or 'ligand(s)' of the invention is a reference to compounds of formula (I), including salts, hydrates and solvates thereof, unless expressly indicated otherwise.

[037] The present invention includes within its scope all isomeric forms of the compounds of formula (I) and salts, hydrates and solvates thereof disclosed herein, including all diastereomeric isomers (including cis/trans isomers), racemates and enantiomers.

[038] In the context of this invention the term "administering" and variations of that term including "administer" and "administration", includes contacting, applying, delivering or providing a compound or composition of the invention to an organism, mammal, or a surface by any appropriate means.


[039] In the context of this specification, the term "mammal" includes humans and individuals of any species of social, economic or research importance including but not limited to members of the genus ovine, bovine, equine, porcine, feline, canine, primates (including human and non-human primates), rodents, murine, caprine, leporine, and avian. In preferred embodiments the mammal is a human.

[040] In the context of this specification, the term "treatment", refers to any and all uses which remedy a disease state or symptoms, prevent the establishment of disease, or otherwise prevent, hinder, retard, or reverse the progression of disease or other undesirable symptoms in any way whatsoever. Thus, for the avoidance of doubt, references herein to 'treatment' include references to curative, palliative and prophylactic treatment.

[041] In the context of this specification the term "effective amount" includes within its meaning a sufficient but non-toxic amount of a compound or composition of the invention to provide the desired therapeutic effect. The exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered, the mode of administration, and so forth. Thus, it is not possible to specify an exact "effective amount". However, for any given case, an appropriate "effective amount" may be determined by one of ordinary skill in the art using only routine experimentation.

Detailed Description of Embodiments of the Invention


[042] The present invention is directed to a selection of thiosemicarbazone compounds that have antiproliferative properties and which may therefore be useful in the treatment of cancer. In particular, the present invention relates to the thiosemicarbazone compounds of general formula (I):




wherein R¹ is cyclohexyl or ethyl;

and salts, hydrates and solvates thereof.

[043] More particularly, the present invention relates to di-2-pyridylketone 4-ethyl-4-methyl-3-thiosemicarbazone (Dp4e4mT) and di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (Dp4cycH4mT), and to salts, hydrates and solvates thereof:



Dp4e4mT




Dp4cycH4mT

[044] Compounds according to the present invention are iron chelators and can chelate Fe(II) and Fe(III). Accordingly, iron complexes (ie, Fe(II) and Fe(III) complexes) of the compounds of formula (I) are also encompassed by the present invention.

[045] Compounds of formula (I) according to the present invention, or salts, hydrates or solvates thereof, may be prepared by methods known to those skilled in the art, including for example, Schiff base condensation of an imine with a ketone, as described for example in

Advanced Organic Chemistry, 4th Ed (John Wiley & Sons, New York, 1992) and *Vogel's Textbook of Practical Organic Chemistry*, 5th Ed (John Wiley & Sons, New York, 1989).

[046] An exemplary general synthetic scheme for preparing compounds of formula (I) is shown below in Scheme 1:



Scheme 1

[047] The first step involves the formation of a carboxymethyl dithiocarbamate from the reaction of a secondary amine (NHRaRb) with carbon disulfide. The Ra and Rb groups of the secondary amine may be the same or different and may be a linear or a cyclic C_{1-6} alkyl. In preferred embodiments of the invention, according to Scheme 1 Ra is methyl and Rb is ethyl or cyclohexyl. Examples of suitable haloacetates include chloroacetate and bromoacetate. Suitable bases will be well known to those skilled in the art and include, for example, sodium hydroxide, potassium hydroxide, lithium hydroxide, ammonia, diethylamine, and the like. Typically, the first step is carried out at ambient temperature (eg, about 20-25 °C). Standard acid work-up (eg, with aqueous hydrochloric acid, sulphuric acid, etc) yields the carboxymethyl dithiocarbamate.

[048] The next step involves the formation of a thiosemicarbazide intermediate compound by reacting the carboxymethyl dithiocarbamate with hydrazine hydrate. Typically, this step is carried out in water with gentle heating at a temperature in the range of from about 25 °C to about 60 °C. Generally a molar excess of hydrazine hydrate is used.

[049] Next, the thiosemicarbazide compound is reacted in a Schiff-base condensation reaction with di-2-pyridyl ketone to form the thiosemicarbazone compound of formula (I). Typically, this reaction may be carried out in any suitable polar solvent, such as ethanol, propanol, tetrahydrofuran, and the like. The reaction is typically carried out by heating the mixture at reflux for a suitable period of time, which typically may be for about 1 to about 24 hours, for example for about 2 to about 8 hours, more typically for about 2 to about 4 hours. Optionally, water produced

during the condensation reaction may be removed by the inclusion of a drying agent, eg TiCl_4 or a molecular sieve, or by azeotropic distillation.

[050] Salt forms of the compounds of formula (I) may be readily prepared using techniques known to those skilled in the art. For example, acid addition salts may be prepared by dissolving a compound of formula (I) in a suitable non-polar solvent, such as hexane, dichloromethane, etc, and stirring with an aqueous acid corresponding to the desired salt. For example, hydrochloric acid would yield the hydrochloride salt, nitric acid would yield the nitrate salt, sulfuric acid would yield the sulfate salt, etc.

[051] Compounds of general formula (I) or their salts, hydrates and solvates may be purified using standard techniques known to those skilled in the art. In preferred embodiments, the compounds of formula (I) may be purified by crystallisation from a suitable solvent or mixture of solvents. Suitable solvents would be known to those skilled in the art and include, for example, methanol, ethanol, acetonitrile, ethyl acetate, N,N-dimethylformamide, dimethylsulfoxide, and mixtures thereof. In other embodiments the product may be recrystallised from a solvent mixture comprising one or more organic solvents, such as those listed above, and water. After purification, compounds of general formula (I) may be substantially pure. For example, the compounds of formula (I) may be isolated in a form which is at least about 80%, 85%, 90%, 95%, 98%, or 99% pure.

Therapy

[052] The present invention also relates to the use of thiosemicarbazone compounds of general formula (I) and salts, hydrates and solvates thereof, in therapy. In particular, the thiosemicarbazone compounds of formula (I) have antiproliferative properties and therefore may be useful in the treatment of cancer. The thiosemicarbazone compounds of the present invention are iron chelators. The compounds of the invention may be useful for the treatment of a wide variety of cancers (tumours), including but not limited to, melanoma, skin cancer, breast cancer, prostate cancer, bladder cancer, liver cancer, gastrointestinal cancer, colon and rectal cancer, brain cancer, head and neck cancer, bone cancer, pancreatic cancer, uterine cancer, ovarian cancer, cervical cancer, lung cancer as well as haematological tumours (eg, leukaemias and lymphomas). In particularly preferred embodiments the cancer is pancreatic cancer. In other particularly preferred embodiments the cancer is lung cancer. In other preferred embodiments the cancer is brain cancer. In preferred embodiments the compounds of the invention are useful for the treatment of solid tumours. In other preferred embodiments the compounds of the invention are useful for the treatment of non-solid tumours.

[053] Pancreatic cancer is a devastating disease being fatal in 98-100% of cases within the first 5 years of diagnosis, with the survival from this disease being the same today as it was 20 years ago. The best treatment currently available for pancreatic cancer is the anti-cancer agent, gemcitabine, which is an analogue of the nucleoside, deoxycytidine. Gemcitabine is a prodrug

which is converted within the cell to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). The success of gemcitabine in pancreatic cancer treatment has been limited. In fact, clinical trials using this agent have found that on average it increases the life-span of patients by only about 3 months. Gemcitabine has been combined with other anticancer agents such as 5-fluorouracil (5-FU) resulting in some improvement of its activity. However, the prognosis for pancreatic cancer patients remains dismal.

[054] Surprisingly, the thiosemicarbazone compounds of the present invention, or salts, hydrates or solvates thereof, advantageously show antiproliferative properties which are at least as good as, and preferably better than, known anticancer agents. For example, in preferred embodiments the thiosemicarbazone compounds of the invention are more effective in inhibiting proliferation of cancer cells (eg, pancreatic cancer cells) when compared to gemcitabine and 5-fluorouracil. The compounds of the present invention (used alone or in combination with other anticancer agents, or as part of a therapeutic regimen), are therefore alternative anticancer agents possessing one or more advantageous therapeutic properties compared to existing anticancer agents.

[055] Another surprising and advantageous feature of the present invention is that the thiosemicarbazone compounds of the present invention, or salts, hydrates or solvates thereof may substantially inhibit pancreatic tumor growth, which is well known to be a particularly aggressive form of cancer. The compounds of the present invention may therefore be used, alone or in combination with other anticancer agents or as part of a therapeutic regimen, in the treatment of pancreatic cancer. In preferred embodiments the thiosemicarbazone compound is Dp4e4mT or a salt or hydrate thereof. In other preferred embodiments the thiosemicarbazone is Dp4cycH4mT or a salt or hydrate thereof.

[056] A further surprising and advantageous feature of the present invention is that the thiosemicarbazone compounds of the present invention may be more effective and less toxic than the potent antiproliferative thiosemicarbazone compound di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT). In particularly preferred embodiments, the thiosemicarbazone compounds of the present invention, eg, Dp4cycH4mT or Dp4e4mT, show substantially less cardiotoxicity than Dp44mT.

[057] The protein myoglobin (Mb) plays an important role in oxygen storage and donation to muscles and is a monomeric counterpart to hemoglobin. In cancer clinical trials involving Triapine[®], induction of methemoglobinemia and hypoxia has been noted as a dose-limiting side effect (Attia S, Kolesar J, et al., (2008). *Invest New Drugs* 26: 369-379 ; Ma B, Goh BC, et al. (2008). *Invest New Drugs* 26: 169-73). In patients that are undergoing chemotherapy for cancer, this complication is undesirable as these patients often have reduced respiratory performance. Accordingly, the excessive production of metHb reduces the clinical utility of Triapine[®]. The compounds of the present invention, in particular the compound Dp4cycH4mT, possess a further advantage over other anticancer agents because they do not induce methaemoglobin (*metHb*)

and/or metmyoglobin (*metMb*) formation, or the compounds induce metHb and/or metMb formation to a significantly less extent than other anticancer agents, such as Dp44mT and Triapine®, while maintaining anti-tumor activity.

Formulations

[058] In accordance with the present invention, when used for the treatment or prevention of an infection, disease, or disorder, compound(s) of the invention may be administered alone or in combination with other agents as part of a therapeutic regimen. The compounds may be administered as a pharmaceutical or veterinarial formulation which comprises at least one compound according to the invention. The compound(s) may also be present as suitable salts, including pharmaceutically acceptable salts.

[059] Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).

[060] In other embodiments the compound(s) of the present invention may be formulated in combination with one or more other therapeutic agents.

[061] In other embodiments of the present invention, the compounds of the invention may be included in combination treatment regimens with surgery and/or other known treatments or therapeutic agents, such as other anticancer agents, in particular, chemotherapeutic agents, radiotherapeutic agents, and/or adjuvant or prophylactic agents. Suitable agents are listed, for example, in the Merck Index, *An Encyclopaedia of Chemicals, Drugs and Biologicals*, 12th Ed., 1996, the entire contents of which are incorporated herein by reference.

[062] For example, when used in the treatment of solid tumours, compounds of the present invention may be administered with one or more chemotherapeutic agents or combinations thereof, such as: adriamycin, taxol, docetaxel, fluorouracil, melphalan, cisplatin, alpha interferon, COMP (cyclophosphamide, vincristine, methotrexate and prednisone), etoposide, mBACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine and dexamethasone), PROMACE/MOPP (prednisone, methotrexate (w/leucovin rescue), doxorubicin, cyclophosphamide, taxol, etoposide/mechlorethamine, vincristine, prednisone and procarbazine), vincristine, vinblastine, angiostatin, TNP-470, pentosan polysulfate, platelet factor 4, angiostatin, LM-609, SU-101, CM-101, Techgalan, thalidomide, SP-PG and the like.

[063] Other examples of anticancer agents include alkylating agents such as nitrogen mustards (eg, mechlorethamine, melphalan, chlorambucil, cyclophosphamide, (L-sarcosine), and ifosfamide), ethylenimines and methylmelamines (eg, hexamethylmelamine, thiotepa), alkylsulfonates (eg, busulfan), nitrosoureas (eg, carmustine, lomustine, semustine, streptozocin), triazines (eg, dacarbazine (dimethyltriazeno-imidazolecarboxamide), temozolomide), folic acid

analogues (eg, methotrexate), pyrimidine analogues (eg, 5-fluorouracil, floxuridine, cytarabine, gemcitabine), purine analogues (eg, 6-mercaptopurine, 6-thioguanine, pentostatin (2'-deoxycoformycin) cladribine, fludarabine), vinca alkaloids (eg, vinblastine, vincristine), taxanes (eg, paclitaxel, docetaxel), epipodophyllotoxins (eg, etoposide, teniposide), camptothecins (topotecan, irinotecan), antibiotics (eg, actinomycin D, daunorubicin (daunomycin, rubidomycin), doxorubicin, bleomycin, mitomycin C, methramycin), enzymes (eg, L-asparaginase), interferon-alpha, interleukin-2, cisplatin, carboplatin, mitoxantrone, hydroxyurea, procarbazine, mitotane, aminoglutethimide, imatinib, adrenocorticosteroids (eg, prednisone), progestins (eg, hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate), oestrogens (eg, diethylstilbestrol, ethinyl estradiol), antiestrogen (eg, tamoxifen, anastrozole), androgens (eg, testosterone propionate, fluoxymesterone), antiandrogens (eg, flutamide), and gonadotropin-releasing hormone analogues (eg, leuprolide).

[064] In particularly preferred embodiments one more compounds of the invention may be used in combination with gemcitabine or 5-fluorouracil, or in combination with gemcitabine and 5-fluorouracil.

[065] Combination regimens may involve the active agents being administered together, sequentially, or spaced apart as appropriate in each case. Combinations of active agents including compounds of the invention may be synergistic.

[066] By pharmaceutically acceptable salt it is meant those salts which, within the scope of sound medical judgement, are suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. Acid addition salts, such as hydrochloride salts, are a particularly preferred embodiment of the invention.

[067] For example, suitable pharmaceutically acceptable salts of compounds according to the present invention may be prepared by mixing the compounds of the invention with a pharmaceutically acceptable acid (including inorganic and organic acids) or a pharmaceutically acceptable base (including inorganic and organic bases). Suitable pharmaceutically acceptable salts of the compounds of the present invention therefore include acid addition salts and base salts.

[068] Suitable pharmaceutically acceptable acids include but are not limited to acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethenesulfonic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, pantoic acid, pantothenic acid, phosphoric acid, oxalic acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid, and the like. Presently preferred acid addition salts are hydrochloric, hydrobromic, phosphoric, and sulfuric salts, and most particularly preferred is the hydrochloric salt.

[069] Suitable base salts may be formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.

[070] Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.

[071] S. M. Berge *et al.* describe pharmaceutically acceptable salts in detail in *J. Pharmaceutical Sciences*, 1977, 66:1-19 and a review on suitable salts is provided by Handbook of Pharmaceutical Salts: Properties, Selection, and Use by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002), both of which are incorporated herein in their entirety.

[072] The salts can be prepared *in situ* during the final isolation and purification of the compounds of the invention, or separately by reacting the free base compound with a suitable organic acid. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, triethanolamine and the like.

[073] Convenient modes of administration of compounds of the invention include parenteral (eg, subcutaneous, intravenous, intramuscular, intradermal, intraperitoneal, intrathecal, intraocular, intranasal, intraventricular injection or infusion techniques), intraperitoneal, oral administration, inhalation, transdermal application, topical creams or gels or powders, or rectal administration. Depending on the route of administration, the formulation and/or compound may be coated with a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the therapeutic activity of the compound.

[074] Dispersions of the compounds according to the invention may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, pharmaceutical preparations may contain a preservative to prevent the growth of microorganisms.

[075] Pharmaceutical compositions suitable for injection include sterile aqueous solutions (for suitably water soluble active agents) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Ideally, the composition is stable under

the conditions of manufacture and storage and may include a preservative to stabilise the composition against the contaminating action of microorganisms such as bacteria and fungi.

[076] In one embodiment of the invention, the compound(s) of the invention may be administered orally, for example, with an inert diluent or an assimilable edible carrier. The compound(s) and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into an individual's diet. For oral therapeutic administration, the compound(s) may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Suitably, such compositions and preparations may contain at least 1% by weight of active compound. The percentage of the compound(s) of the invention in pharmaceutical compositions and preparations may, of course, be varied. For example, the amount may conveniently range from about 2% to about 90%, about 5% to about 80%, about 10% to about 75%, about 15% to about 65%; about 20% to about 60%, about 25% to about 50%, about 30% to about 45%, or about 35% to about 45%, of the weight of the dosage unit. The amount of compound in therapeutically useful compositions is such that a suitable dosage can be obtained. Suitable doses may be obtained by single or multiple administrations.

[077] The term "pharmaceutically acceptable carrier" is intended to include solvents, dispersion media, coatings, anti-bacterial and anti-fungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the compound, use thereof in the therapeutic compositions and methods of treatment and prophylaxis is contemplated. Supplementary active compounds may also be incorporated into the compositions according to the present invention. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage.

[078] The term "dosage unit form" as used herein refers to physically discrete units suited as unitary dosages for the individual to be treated; each unit containing a predetermined quantity of compound(s) calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The compound(s) may be formulated for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in an acceptable dosage unit. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

[079] In one embodiment, the carrier may be an orally administrable carrier.

[080] Another form of a pharmaceutical composition is a dosage form formulated as enterically coated granules, tablets or capsules suitable for oral administration.

[081] Also included in the scope of this invention are delayed or extended release formulations.

[082] In a preferred embodiment, the compound(s) of the invention may be administered by injection. In the case of injectable solutions, the carrier may be a solvent or dispersion medium

containing, for example, water (eg, water-for-injection), saline, 5% glucose solution, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants (eg, polysorbate 80). Prevention of the action of microorganisms can be achieved by including various anti-bacterial and/or anti-fungal agents. Suitable agents are well known to those skilled in the art and include, for example, parabens, chlorobutanol, phenol, benzyl alcohol, ascorbic acid, thimerosal, and the like. In many cases, it may be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminium monostearate and gelatin.

[083] Sterile injectable solutions can be prepared by incorporating the analogue in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilisation. Generally, dispersions may be prepared by incorporating the analogue into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.

[084] Tablets, troches, pills, capsules and the like can also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules can be coated with shellac, sugar or both. A syrup or elixir can contain the analogue, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the analogue can be incorporated into sustained-release preparations and formulations.

[085] Preferably, the pharmaceutical composition may further include a suitable buffer to minimise acid hydrolysis. Suitable buffer agent agents are well known to those skilled in the art and include, but are not limited to, phosphates, citrates, carbonates and mixtures thereof.

[086] Single or multiple administrations of the pharmaceutical compositions according to the invention may be carried out. One skilled in the art would be able, by routine experimentation, to determine effective, non-toxic dosage levels of the compound and/or composition of the invention and an administration pattern which would be suitable for treating the diseases and/or infections to which the compounds and compositions are applicable.

[087] Further, it will be apparent to one of ordinary skill in the art that the optimal course of treatment, such as the number of doses of the compound or composition of the invention given per day for a defined number of days, can be ascertained using conventional course of treatment determination tests.

[088] Generally, an effective dosage per 24 hours may be in the range of about 0.0001 mg to about 1000 mg per kg body weight; suitably, about 0.001 mg to about 750 mg per kg body weight; about 0.01 mg to about 500 mg per kg body weight; about 0.1 mg to about 500 mg per kg body weight; about 0.1 mg to about 250 mg per kg body weight; or about 1.0 mg to about 250 mg per kg body weight. More suitably, an effective dosage per 24 hours may be in the range of about 1.0 mg to about 200 mg per kg body weight; about 1.0 mg to about 100 mg per kg body weight; about 1.0 mg to about 50 mg per kg body weight; about 1.0 mg to about 25 mg per kg body weight; about 5.0 mg to about 50 mg per kg body weight; about 5.0 mg to about 20 mg per kg body weight; or about 5.0 mg to about 15 mg per kg body weight.

[089] Alternatively, an effective dosage may be calculated according to the Body Surface Area (BSA) of the patient to be treated. The BSA of a patient may be readily calculated using methods known to those skilled in the art. A suitable dose generally may be up to about 500 mg/m². For example, generally, an effective dosage may be in the range of about 10 to about 500 mg/m², about 25 to about 350 mg/m², about 25 to about 300 mg/m², about 25 to about 250 mg/m², about 50 to about 250 mg/m², and about 75 to about 150 mg/m².

[090] The invention will now be described with reference to the following non-limiting examples.

EXAMPLES

Example 1 – Synthesis of Dp4cych4mT, Dp4e4mT and corresponding hydrochloric salts

Methodology:

[091] The chelators di-2-pyridylketone 4-ethyl-4-methyl-3-thiosemicarbazone (*Dp4e4mT*) and di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (*Dp4cycH4mT*) were synthesized using a combination of established methods (Scovill, J P (1990). *Phosphorous, Sulphur and Silicon* 60: 15-19; Richardson, D.R. et al (2006). *J Med Chem.* 49: 6510-6521). Briefly, carbon disulphide (0.2 mol) was added drop-wise to N-methylcyclohexylamine or N-ethylmethylamine (0.2 mol) in NaOH solution (250 mL, 0.8 M) and allowed to react until the organic layer almost disappeared. Next, sodium chloroacetate (0.2 mol) was added to the aqueous extract and allowed to react over-night at room temperature. The addition of concentrated HCl (25 mL) gave the solid carboxymethyl thiocarbamate intermediate. Approximately 0.08 mol of carboxymethyl thiocarbamate intermediate was dissolved in 20 mL hydrazine hydrate plus 10 mL of water. This was followed by five cycles of gentle heating (until fuming) and cooling. The solution was then allowed to stand until fine white crystals of thiosemicarbazide intermediate formed. A solution of

the thiosemicarbazide intermediate (10 mmol) in water (15 mL) was added to di-2-pyridyl ketone (10 mmol) dissolved in EtOH (15 mL). Next, 5 drops of glacial acetic acid were added and the mixture was refluxed for 2 h and cooled to 5°C to give the yellow Dp4cycH4mT or Dp4e4mT precipitate, respectively. Finally, Dp4cycH4mT or Dp4e4mT was dissolved in minimum volume of cold hexane and equimolar HCl was added to give the corresponding HCl salt. The synthesis scheme is shown in Figure 1B.

Results:

[092] Dp4cycH4mT: Yield 64% (from CS₂). Anal. calcd. For C₁₉H₂₃N₅S: C, 64.56; H, 6.56; N, 19.81%. Found: C, 64.51; H, 6.47; N, 20.04%.

[093] Dp4cycH4mT.HCl.5H₂O Yield 87% (from Dp4cycH4mT). Anal. calcd. For C₁₉H₂₃N₅S.HCl.5.5H₂O: C, 47.54; H, 7.14; N, 14.59%. Found: C, 47.06; H, 6.65; N, 14.95%. ¹H-NMR (DMSO-*d*₆): δ 8.82 (d, 1H), 8.61 (d, 1H), 8.04-7.90 (m, 3H), 7.62-7.56 (t, 2H), 7.50-7.46 (t, 1H), 3.18 (s, 3H), 1.83-1.49 (m, 7H), 1.40-1.10 (m, 3H). MS *m/z* (%) 376.3 (M + H, 5), 376 (M + Na, 34).

[094] Dp4e4mT: Yield 44% (from CS₂). Anal. calcd. For C₁₅H₁₆N₄S: C, 63.4; H, 5.7; N, 19.7%. Found: C, 62.8; H, 5.9; N, 19.5%.

[095] Dp4e4mT.HCl.5.5H₂O Yield 91% (from Dp4e4mT). Anal. calcd. For C₁₅H₁₇N₅S.HCl.5.5H₂O: C, 41.42; H, 6.72; N, 16.10%. Found: C, 41.31; H, 6.45; N, 15.95%. ¹H-NMR (DMSO-*d*₆): δ 8.84 (d, 1H), 8.66 (d, 1H), 8.13-8.09 (t, 1H), 8.04-7.97 (dt, 2H), 7.67-7.59 (dt, 3H), 3.32 (s, 3H), 1.20 (s, 3H). MS *m/z* (%) 322.0 (M + Na, 46), 620.87 (M; dimer, + Na, 100).

Example 2 – Anti-proliferative Activity of Dp4e4mT and Dp4cycH4mT

Methodology:

[096] SK-N-MC human neuroepithelioma cells were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA) and cultured according to the methods described previously (Richardson, D R et al (1995). *Blood* 86: 4295-306). The cells were maintained in minimum essential media (MEM; Invitrogen, CA, USA) which contained 10% fetal calf serum (FCS; JRH Biosciences, Kansas, USA), 1% non-essential amino acids (Gibco, Victoria, Australia), 1% penicillin/streptomycin/glutamine (Gibco, VIC, Australia) and fungizone (0.28 ng/mL; Squibb Pharmaceuticals, Montreal, Canada).

[097] The pancreatic cancer cell lines, including MIAPaCa-2, PANC 1, CAPAN-2 and CFPAC-1 were a generous gift from Prof. Andrew Biankin (Garvan Institute, NSW, Australia). The MIAPaCa-2, PANC 1 and CFPAC-1 cell lines were grown in DMEM medium (Invitrogen) and CAPAN-2 cells were grown in McCoy's medium (Invitrogen). All media was supplemented with 10% (v/v) fetal calf serum (Invitrogen), 1% (v/v) non-essential amino acids (Invitrogen), 1% (v/v) sodium pyruvate (Invitrogen), 2 mM L-glutamine (Invitrogen), 100 µg/mL of streptomycin (Invitrogen), 100 U/mL penicillin (Invitrogen), and 0.28 µg/mL of fungizone.

Results:

[098] The ability of the compounds to inhibit cellular proliferation was assessed initially in SK-N-MC cells by the MTT assay. Both Dp4e4mT and Dp4cycH4mT exhibited anti-proliferative activity significantly greater than that of DFO ($p < 0.05$) and the iron chelator 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (**311**) ($p < 0.05$) in SK-N-MC cells (Figure 2; Table 1), with IC_{50} values of 0.0041 and 0.013 μ M respectively.

[099] Table 1. Anti-proliferative activity of Dp4e4mT and Dp4cycH4mT against SK-N-MC neuroepithelioma. IC_{50} (μ M) values of Dp4e4mT and Dp4cycH4mT in the SK-N-MC neuroepithelioma cell line as determined by the MTT assay. Cells were seeded and allowed to attach to wells for 24 h and then incubated for 72 h at 37°C with control medium or the chelators. Results are mean \pm SD (3 experiments)

	IC_{50} (μ M)
DFO	13.4 \pm 3.7
311	0.72 \pm 0.32
Dp4mT	0.34 \pm 0.11
Dp4m4eT	0.0041 \pm 0.0015
Dp4cycH4mT	0.013 \pm 0.0016

[0100] The chelators Dp4e4mT and Dp4cycH4mT are structurally-related to the compound di-2-pyridylketone 4-methyl-3-thiosemicarbazone (Dp4mT) through the replacement of a hydrogen atom at the terminal nitrogen (N4) by alkyl functional groups. The formation of Dp4e4mT involves the substitution of a hydrogen atom at N4 of Dp4mT with an ethyl group, whereas Dp4cycH4mT features a cyclohexyl substituent. These structural modifications were found to significantly ($p < 0.001$) increase anti-proliferative activity of both analogues relative to Dp4mT, which has an IC_{50} value of 0.34 μ M (Figure 2, Table 1).

[0101] To further examine the spectrum of anti-proliferative activity, Dp4cycH4mT was tested against pancreatic cancer *in vitro*, performing MTT proliferation assays with PANC 1, MIAPaCa-2, CFPAC-1 and CAPAN-2 pancreatic cancer cells. As a comparison, currently used treatments for pancreatic cancer including gemcitabine and 5-fluorouracil were also tested. The iron chelator, DFO, was included as a positive control.

[0102] In MIAPaCa-2, PANC 1 and CAPAN-2 cells, the highest anti-proliferative activity was observed with Dp4cycH4mT (Figure 3A, B and C) with IC_{50} values being significantly ($p < 0.01$) lower compared to gemcitabine and 5-fluorouracil (Table 2A). In fact, the IC_{50} values for Dp4cycH4mT were at least 100-fold and 1000-fold lower in 2 out of the 4 cell types when compared to gemcitabine and 5-fluorouracil, respectively (Table 2A). The positive control, DFO, had relatively low anti-proliferative activity.

[0103] Table 2A. Anti-proliferative activity of Dp4cycH4mT against pancreatic cancer cell lines. Growth and antiproliferative activity IC_{50} (μM) values of Dp4cycH4mT in a variety of pancreatic cell lines and in comparison to DFO and the clinically used drugs gemcitabine and 5-fluorouracil as determined by the MTT assay. Cells were seeded and allowed to attach to wells for 24 h and then incubated for 72 h at 37°C with control medium or the chelators. Results are mean \pm SD (3 experiments).

	IC_{50} (μM)			
	DFO	Dp4cycH4mT	Gemcitabine	5-fluorouracil
MIAPaCa-2	38.7 \pm 6.2	0.009 \pm 0.0003	0.02 \pm 0.005	24.3 \pm 6.3
PANC 1	9.5 \pm 1.4	0.05 \pm 0.002	11.0 \pm 0.8	62.3 \pm 6.5
CAPAN-2	7.0 \pm 5.4	0.04 \pm 0.008	40.8 \pm 4.7	59.2 \pm 24.2
CFPAC-1	14.7 \pm 3.1	0.4 \pm 0.2	0.02 \pm 0.02	41.2 \pm 1.1

[0104] In contrast to the other cell types, where the thiosemicarbazones had the highest anti-proliferative activity, CFPAC-1 cells were the most sensitive to gemcitabine. In fact, the IC_{50} value for gemcitabine was significantly ($p < 0.05$) lower than that of Dp4cycH4mT (Figure 3D and Table 2A). Dp4cycH4mT had lower IC_{90} values than gemcitabine in CFPAC-1 cells (Figure 3D, Table 2B). Thus, these data suggest that the thiosemicarbazones have the potential to almost completely inhibit proliferation of this cell type *in vitro* when used at higher doses, while the anti-proliferative activity of gemcitabine is more limited (Figure 3D) demonstrating the difference in response between the different cell types.

[0105] Table 2B. Anti-proliferative activity of Dp4cycH4mT against pancreatic cancer cell lines. IC_{90} (μM) values of Dp4cycH4mT in a variety of pancreatic cell lines and in comparison to DFO and the clinically used drugs gemcitabine and 5-fluorouracil as determined by the MTT assay. Cells were seeded and allowed to attach to wells for 24 h and then incubated for 72 h at 37°C with control medium or the chelators. Results are mean \pm SD (3 experiments).

	IC_{90} (μM)			
	DFO	Dp4cycH4mT	Gemcitabine	5-fluorouracil
MIAPaCa-2	> 80	> 5	> 5	> 5
PANC 1	> 80	> 5	> 5	> 20
CAPAN-2	> 80	> 5	> 5	> 80
CFPAC-1	> 80	5.4 \pm 1.1	30.4 \pm 2.2	> 40

Example 3 – Cellular Fe Efflux and Inhibition of Fe Uptake from Transferrin by Dp4e4mT and Dp4cycH4mT

Methodology:

Iron Efflux Assay

[0106] The effect of the iron chelators Dp4e4mT and Dp4cycH4mT on the release of ^{59}Fe from pre-labeled SK-N-MCs neuroepithelioma cells were examined using established methods (eg, Baker, E et al (1992). *Hepatology* 15: 492-501). SK-N-MC cells were initially plated onto 35 mm culture dishes and incubated at 37°C in a 5% CO_2 /95% air humidified incubator until they were approximately 80% confluent. After this, the cells were pre-labeled through a 3 h incubation at 37°C with appropriate media containing 0.06 mg/mL ^{59}Fe -Tf (prepared as outlined in Baker, E et al (1992). *Hepatology* 15: 492-501). The culture dishes were then placed on ice, the supernatant containing excess ^{59}Fe -Tf was aspirated and the cells washed 4 times with ice-cold PBS. The cells were then incubated for a further 3 h at 37°C with media containing 25 μM chelators or media alone (control). After 3 h the culture dishes were again placed on ice, the media was collected in counting tubes and this provided a measurement of released ^{59}Fe . Ice-cold PBS (1 mL) was added to plates containing cells and cells were scraped from the plastic surface using a Teflon spatula and also collected in counting tubes. These tubes represent the intracellular ^{59}Fe content. Results are expressed as total ^{59}Fe released as a percentage of total ^{59}Fe present. Radioactivity was measured using a Wallac Wizard 3" Gamma Counter (PerkinElmer, MA, USA).

Iron Uptake Assay

[0107] The effect of the iron chelators Dp4e4mT and Dp4cycH4mT on the ability of SK-N-MCs to obtain ^{59}Fe from media was examined using established methods (Richardson, D R, et al. (1995). *Blood* 86: 4295-306; Baker, E et al (1992). *Hepatology* 15: 492-501). Cells were cultured in the same way as for the iron efflux experiments. Once the cells were approximately 80% confluent they were incubated for 3 h at 37°C with media containing 25 μM chelators or media alone (control). ^{59}Fe -Tf (0.06 mg/mL) was added to the media. At the end of the incubation the culture dishes were placed on ice, the media aspirated, and the cells washed 4 times with ice cold PBS. Protease (1 mL; 1 mg/mL; Sigma-Aldrich, NSW, Australia) solution was added to each plate and allowed to incubate on ice for 30 min. This facilitated the removal of membrane bound ^{59}Fe -Tf. Cells were then scraped from the plastic surface using a Teflon spatula and collected in Eppendorf tubes. These were centrifuged at 10000 rpm and 4°C for 3 min. The supernatant was then transferred into counting tubes and the cell pellet resuspended in PBS before also being transferred into another set of counting tubes. Radioactivity was measured using a Wallac Wizard 3" Gamma Counter (PerkinElmer, MA, USA). Results are expressed as average ^{59}Fe content of the cellular fraction as a percentage of the control value.

Example 3a – Cellular Fe Efflux Mediated by Dp4e4mT and Dp4cycH4mT

[0108] All dipyriddy thiosemicarbazone compounds exhibited significantly increased iron efflux activity compared to control cells ($p < 0.001$) (Figure 4A). Control cells released 7% of the total cellular ^{59}Fe after a 3 h re-incubation with fresh media (Figure 4A). The compound Dp4e4mT was able to mobilise 38% of cellular ^{59}Fe (Figure 4A), which was comparable to the compound Dp4mT, which mobilised 42% cellular Fe. The compound Dp4cycH4mT only mobilised 22% of cellular ^{59}Fe , which was similar to the clinically used chelator DFO that mobilised 16% of cellular Fe, but less than the structurally related analogue Dp4mT (Figure 4A). This suggests that Dp4cycH4mT may have other mechanisms of action besides Fe chelation considering its marked anti-proliferative activity relative to DFO and Dp4mT (Table 1). The iron efflux profile of the compound 311 was also examined as an internal standard and agreed with previous studies.

Example 3b – Inhibition of Cellular ^{59}Fe Uptake from ^{59}Fe Transferrin by Dp4e4mT and Dp4cycH4mT

[0109] To further characterise Fe chelation efficacy, the ability of Dp4e4mT and Dp4cycH4mT to inhibit the uptake of ^{59}Fe from ^{59}Fe -Tf was compared to the structurally related compound, Dp4mT. Dp4e4mT limited cellular ^{59}Fe uptake to 12% of the control, which was comparable to Dp4mT, which limited cellular ^{59}Fe uptake to 6% of the control (Figure 4B). Dp4cycH4mT was less effective than either Dp4e4mT or Dp4mT, limiting ^{59}Fe uptake to 21% (Figure 4B). However, all compounds showed considerably greater activity than DFO ($p < 0.001$), which limited ^{59}Fe uptake to only 84% of what was seen in untreated cells (Figure 4B). Similarly to the iron efflux studies, the compound 311 was also examined as an internal standard and limited cellular ^{59}Fe uptake to 5% which agreed with previous studies (eg, Richardson, D R et al. (1995). *Blood* **86**: 4295-306).

Example 4 – *In-vivo* Inhibition of Tumour Growth by Dp4e4mT and Dp4cycH4mT***Methodology:***

[0110] Female nude mice (BALBc nu/nu), 8-weeks old, were used for the *in vivo* studies and all studies were approved by the Animal Ethics Committee (University of Sydney). Tumor xenografts established by standard techniques (Whitnall, M, J. Howard, et al. (2006). *Proc Natl Acad Sci USA* **103**: 14901-6.). In studies examining the growth of DMS-53 lung carcinoma, exponentially growing cells were harvested and a 1:1 mixture of cell-containing medium and Matrigel[®] (BD Biosciences, MA, USA) prepared using 1×10^7 cells/100 μL . The cell/matrigel mixture was injected s.c. into the right flank of methoxyflurane-anesthetised mice. In studies examining the growth of PANC 1 pancreatic cancer cells, each mouse was injected subcutaneously with 2×10^6 PANC 1 cells suspended in Matrigel (BD Biosciences, San Jose, CA, USA). Tumor size was measured by Vernier calipers and tumour volume calculated as

described previously (Balsari, A., M. Tortoreto, et al. (2004). *Eur J Cancer* **40**: 1275-81.). Once the tumours reached an average of 90 mm³, the treatment began (Day 0; Figure 5).

[0111] Dp44mT and Dp4cycH4mT.HCl were dissolved in 30% propylene glycol in 0.9% saline and injected intravenously (*via* the tail vein) 5 days/week or given by oral gavage 5 days/week at the dosage specified in the respective study.

[0112] In the PANC 1 study, gemcitabine was dissolved in 15% propylene glycol in 0.9% saline and injected intra-peritoneally every 3rd day and each group ($n = 8$) received either gemcitabine (5 mg/kg), Dp44mT (0.4 mg/kg), Dp4cycH4mT.HCl (5 mg/kg) or vehicle control. In the PANC 1 study, the vehicle control group was subdivided into two groups ($n = 4$) with one receiving an intravenous injection of 30% propylene glycol in 0.9% saline 5 days/week, which acted as a control for the iron chelator treatment group. The other group received 15% propylene glycol in 0.9% saline intra-peritoneally every 3rd day and was the appropriate control for the gemcitabine treatment. Once control tumours reached 1,000 mm³, the animals were euthanized due to ethical requirements.

Hematology, Biochemistry and Histology:

[0113] Upon completion of the *in vivo* experiment, blood was collected by cardiac puncture and hematologic indices assayed by standard methods (Dunn, L.L., et al (2006) *Carcinogenesis* **27**: 2157-69). Tissues, including organs and tumours, were embedded in paraffin blocks and sectioned. Three different stains were utilized, namely hematoxylin and eosin (H & E), Pearl's or Gomori-Trichrome. In the PANC 1 tumour xenograft study, the histological analysis and quantification of pathological features was performed by an independent veterinary pathologist (Dr Terrence Rothwell, Rothwell Consulting, Avalon Beach, NSW, Australia).

Statistical Analysis:

[0114] Data were compared by using Student's *t*-test. Results were expressed as mean \pm SEM unless otherwise indicated. Data were considered statistically significant when $p < 0.05$.

Example 4a – Effect of Dp4e4mT.HCl by i.v Administration on the *in-vivo* inhibition of DMS-53 Human Lung Carcinoma

[0115] A potent response to Dp4e4mT.HCl was observed in the DMS-53 xenograft model in nude mice (Figure 5). After 25 days, average net tumour size in control vehicle-treated mice was 780% of the initial tumour volume, while in mice treated with 4 or 6 mg/kg Dp4e4mT, net tumour size was 120-122% of the initial volume. This was comparable to the degree of tumour inhibition exhibited by 0.75 mg/kg Dp44mT which inhibited the growth of the tumour to 122% of the initial tumour volume (Figure 5).

Example 4a(i) – Biologic Assessment Following i.v. Dp4e4mT Treatment:**Weight Loss and Hematological Analyses in Mice Bearing DMS-53 Human Lung****Carcinoma**

[0116] In the DMS-53 lung carcinoma study mice treated *i.v.* with 0.75 mg/kg Dp44mT lost 9% of initial weight (Table 3). In contrast, mice treated with Dp4e4mT.HCl at 4 or 6 mg/kg experienced weight loss of 0.6% and 7% of initial body weight, respectively, (Table 3) after 25 days of treatment. Control mice in this experiment lost 6% of initial body weight (Table 3).

[0117] Table 3. Growth of DMS-53 Lung carcinoma in nude mice Dp4e4mT i.v administration study: Body and organ weights (g).

Experimental Groups (n = 6)					
Organ	Control	Dp4e4mT-HCl (6 mg/kg)	Dp4e4mT-HCl (4 mg/kg)	Dp4e4mT-HCl (1.5 mg/kg)	Dp44mT (0.75 mg/kg)
Body weight loss (% initial weight)	95.45 ± 3.41	93.38 ± 3.96	99.41 ± 1.75	95.14 ± 0.97	91.01 ± 5.3
Liver	1.05 ± 0.13	1.1 ± 0.08	1.03 ± 0.02	1.01 ± 0.02	1.04 ± 0.05
Spleen	0.13 ± 0.02	0.089 ± 0.01	0.08 ± 0.003	0.11 ± 0.01	0.13 ± 0.02
Kidney	0.26 ± 0.02	0.27 ± 0.01	0.26 ± 0.01	0.26 ± 0.01	0.23 ± 0.01
Heart	0.09 ± 0.01	0.11 ± 0.01	0.1 ± 0.01	0.1 ± 0.004	0.11 ± 0.01
Brain	0.31 ± 0.02	0.36 ± 0.03	0.36 ± 0.01	0.26 ± 0.13	0.32 ± 0.01
Tumour	0.97 ± 0.08	0.04 ± 0.03**	0.11 ± 0.09***	0.48 ± 0.6*	0.1 ± 0.02**

Results are mean ± SEM * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$ compared to vehicle control as determined by Student's T test

[0118] In terms of haematology, after 2 weeks of treatment with Dp44mT at 0.75 mg/kg or Dp4e4mT.HCl at 1.5, 4 or 6 mg/kg, there was no significant change in red blood cell count, haemoglobin or white blood cell count (Table 4). This indicates that at the doses and administration schedule used Dp4e4mT.HCl was well tolerated.

[0119] Table 4. Growth of DMS-53 Lung carcinoma in nude mice Dp4e4mT i.v. administration study: Haematology.

	WBC (10x9 cells/L)	RBC (10x12 cells/L)	HGB (g/L)	HCT	PLT (10x9 cells/L)
Controls					
Average	2.77	10.03	144.67	0.44	874.67
STD	0.57	0.13	8.5	0.03	655.79
Dp4e4mT.HCl (1.5 mg)					
Average	3.34	8.76	150.60	0.4	766.4
STD	1.12	3.31	7.99	0.14	684.19
Dp4e4mT.HCl (4 mg)					
Average	2.94	10.74	153.75	0.47	1224.5
STD	0.56	0.33	4.92	0.01	713.7
Dp4e4mT.HCl (6 mg)					
Average	4.63	9.33	132.33	0.41	1238
STD	2.46	1.01	16.26	0.05	729.11
Dp44mT (0.75 mg)					
Average	5.38	9.87	135.50	0.43	1274.50
STD	1.46	0.83	10.61	0.01	43.13

WBC – white blood cell; RBC – red blood cell; HGB – haemoglobin; HCT – hemacrit;
PLT - platelet

Example 4a(ii) – Effects of Dp4e4mT on Tissue Histology Following i.v. Dp4e4mT Treatment in Mice Bearing DMS-53 Human Lung Carcinoma

[0120] Histological assessment was performed on tissues from the *i.v.* DMS-53 human lung carcinoma experiment. Results are discussed comparing tissues from DMS-53 xenografted mice treated with vehicle, Dp44mT (2 weeks at 0.75 mg/kg) or Dp4e4mT.HCl (2 weeks at 4 mg/kg and 6 mg/kg). In hematoxylin and eosin (H & E) stained sections, no significant differences were found in the histology of the liver, spleen, kidney, brain or tumour from control and chelator treated mice.

[0121] However, myocardial lesions were observed in mice treated with Dp44mT (0.75mg/kg; Figure 6). Such lesions consisted of poorly differentiated foci of necrosis, being replaced with immature fibrous tissue which was evident using Gomori-Trichrome stain (arrow; Figure 6) and was consistent with those described previously for Dp44mT (Whitnall, M., J. Howard, et al. (2006). *Proc Natl Acad Sci USA* 103: 14901-6). However, Dp4e4mT.HCl did not induce myocardial lesions at 4 mg/kg or 6 mg/kg after 2 weeks of i.v. administration (Figure 6).

Example 4b – Effect of Dp4e4mT.HCl by oral Administration on the *in-vivo* Inhibition of DMS-53 Human Lung Carcinoma

[0122] Similarly to what was found when Dp4e4mT.HCl was given by *i.v.* administration (Figure 5), a potent response to Dp4e4mT.HCl by oral gavage was observed in nude mice bearing the DMS-53 xenograft (Figure 7A). After 21 days, average net tumour size in control vehicle-treated mice was 1124% of the initial tumour volume, while in mice treated with 7.5 or 10 mg/kg Dp4e4mT, the net tumour size was 404% and 284% of initial tumour volume, respectively (Figure 7A). Lower doses of Dp4e4mT.HCl (2.5 and 5 mg/kg) also limited tumour growth to 645% and 733% of initial volumes, respectively (Figure 7A).

[0123] Considering tumour weight, at end of the 21 day treatment period, untreated control mice had tumours that weighed, on average, 1.8 g (Figure 7B). Mice treated with Dp4e4mT.HCl at 10 mg/kg by oral gavage showed a potent and significant ($p < 0.0002$) decrease in average tumour weight to 0.46 g (Figure 7B). Lower doses of Dp4e4mT.HCl by oral gavage also significantly inhibited tumour weight (Figure 7B). For example, the lowest dose administered, 2.5 mg/kg, resulted in a significant ($p < 0.002$) reduction in average tumour weight to 0.63 g (Figure 7B).

Example 4b(i) – Biologic Assessment Following Oral Dp4e4mT Treatment:

Weight loss and Hematological Analyses in Mice Bearing DMS-53 Human Lung Carcinoma

[0124] In the DMS-53 lung carcinoma study mice treated orally with Dp4e4mT.HCl, no treatment group showed any significant weight loss compared to the control group (Table 5). For example, control mice maintained 96% of their initial weight, whereas mice treated with the highest dose of Dp4e4mT.HCl (10 mg/kg) retained 94% of their initial weight; indicating that treatment at this dose was well tolerated (Table 5).

[0125] Table 5. Growth of DMS-53 Lung carcinoma in nude mice Dp4e4mT oral administration study: Body and organ weights (g).

Organ	Experimental Groups				
	Control (n = 11)	Dp4e4mT (2.5 mg/kg) (n=8)	Dp4e4mT (5 mg/kg) (n=10)	Dp4e4mT (7.5 mg/kg) (n=9)	Dp44mT (10 mg/kg) (n=9)
Body weight (% initial)	96.3 ± 1.7	94.1 ± 1.3	91.6 ± 2.4	91.6 ± 2.2	93.6 ± 1.8
Liver	0.84 ± 0.04	0.87 ± 0.02	0.77 ± 0.02	0.83 ± 0.03	0.88 ± 0.02
Spleen	0.082 ± 0.003	0.075 ± 0.004	0.075 ± 0.004	0.061 ± 0.009	0.081 ± 0.005
Kidney	0.205 ± 0.003	0.194 ± 0.005	0.187 ± 0.006	0.193 ± 0.008	0.208 ± 0.004
Heart	0.083 ± 0.002	0.078 ± 0.002	0.078 ± 0.002	0.092 ± 0.005	0.102 ± 0.005
Brain	0.367 ± 0.007	0.372 ± 0.006	0.367 ± 0.007	0.356 ± 0.007	0.363 ± 0.008
Lung	0.115 ± 0.003	0.121 ± 0.005	0.117 ± 0.003	0.119 ± 0.004	0.133 ± 0.008
Tumour	1.76 ± 0.24	0.63 ± 0.17**	0.89 ± 0.14**	0.60 ± 0.15**	0.46 ± 0.1***

Values expressed as mean ± SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ compared to vehicle control as determined by Students T-test

[0126] In terms of haematology, after 21 days of treatment with Dp4e4mT.HCl at 2.5, 5, 7.5 or 10 mg/kg, there were significant changes in red blood cell count, haematocrit or white blood cell count (Table 6). Although at 5 mg/kg, Dp4e4mT.HCl significantly ($p < 0.05$) reduced white blood cells and at 10 mg/kg significantly reduced haemoglobin ($p < 0.05$) compared to untreated animals, however the clinical significance of these changes is not clear. Overall, haematology indicated the doses and administration schedule used Dp4e4mT.HCl was well tolerated.

[0127] Serum biochemical analysis showed that Dp4e4mT.HCl treatment at 5 mg/kg significantly ($p < 0.05$) decreased 'total iron binding capacity' (TIBC) relative to the control (53.1 ± 1.2 to $60.7 \pm 2 \mu\text{mol/L}$, respectively; Table 6). However, higher dosage treatment groups did not show suppression of TIBC (Table 6). Additionally, 'unsaturated iron binding capacity' (UIBC) was significantly ($p < 0.01$) increased in the 5 and 7.5 mg/kg Dp4e4mT.HCl treatment group relative to untreated controls but the 10 mg/kg treatment group did not show any significant change (Table 6). Alkaline phosphatase was also significantly elevated ($p < 0.01$) in 10 mg/kg Dp4e4mT/HCl treated mice compared to untreated controls (89.5 ± 4.5 to 68.7 ± 12.8 , respectively; Table 6) and was also significantly elevated in the 2.5 and 7.5 mg/kg groups (Table 6).

Table 6. Haematology and biochemistry

Indices	Units	Treatment Groups (Oral Gavage for 21 days, 3 days/week)				
		Vehicle Control (n=11)	Dp4e4mT 2.5mg/kg (n=8)	Dp4e4mT 5mg/kg (n=10)	Dp4e4mT 7.5mg/kg (n=9)	Dp4e4mT 10mg/kg (n=9)
Hematological indices						
Red Blood Cell (RBC)	10 ¹² /L	10.92 ± 0.10	10.55 ± 0.12	10.26 ± 0.17	10.85 ± 0.14	10.18 ± 0.30
White Blood Cell (WBC)	10 ⁹ /L	2.62 ± 0.20	2.68 ± 0.53	1.80 ± 0.15*	3.08 ± 0.43	3.27 ± 0.36
Haemoglobin (HGB)	g/L	156 ± 1	148 ± 2	143 ± 2	151 ± 2	142 ± 5*
Haematocrit (HCT)	%	0.46 ± 0.004	0.44 ± 0.01	0.43 ± 0.01	0.45 ± 0.01	0.44 ± 0.01
Platelets	10 ⁹ /L	936 ± 79	1047 ± 73	973 ± 49	834 ± 114	917 ± 142
Serum Biochemical indices						
Serum Iron	umol/L	26.8 ± 2.1	25.5 ± 2.0	31.0 ± 1.9	32.8 ± 2.3	21.2 ± 2.0
Total Iron-Binding Capacity (TIBC)	umol/L	60.7 ± 2.0	56.7 ± 2.1	53.1 ± 1.2**	56.8 ± 0.9	60.2 ± 2.3
Unsaturated Iron-Binding Capacity (UIBC)	umol/L	55.1 ± 2.5	57.9 ± 3.5	66.9 ± 2.3**	64.9 ± 2.0**	50.1 ± 2.7
Alkaline Phosphatase (ALP)	U/L	67.7 ± 5.7	85.7 ± 5.0*	61.7 ± 2.0	87.2 ± 4.1*	89.5 ± 4.5**
Alanine Aminotransferase (ALT)	U/L	68.7 ± 12.8	73.1 ± 14.4	44.9 ± 2.8	57.2 ± 12.9	63.4 ± 9.9
Albumin	g/L	32.7 ± 0.6	31.3 ± 0.9	30.4 ± 0.5*	31.3 ± 1.1	29.3 ± 1.6
Cholesterol	mmol/L	2.79 ± 0.19	2.44 ± 0.23	2.63 ± 0.12	2.78 ± 0.24	2.46 ± 0.16
Triglyceride	mmol/L	0.85 ± 0.12	1.00 ± 0.25	0.57 ± 0.05	0.67 ± 0.03	0.94 ± 0.08

Values expressed as mean ± SEM. *p<0.05; **p<0.01; ***p<0.001 compared to their respective vehicle control, as determined using Student's t-test.

Example 4b(ii) – Effects of Dp4e4mT on Tissue Histology Following Oral Dp4e4mT Treatment in Mice Bearing DMS-53 Human Lung Carcinoma

[0128] Histological assessment was performed on tissues from the oral DMS-53 human lung carcinoma experiment. Results are discussed comparing tissues from DMS-53 xenografted mice treated with vehicle, Dp44mT (2 weeks at 0.75 mg/kg) or Dp4e4mT.HCl (3 weeks at 2.5, 5, 7.5 and 10 mg/kg). In hematoxylin and eosin (H & E) stained sections, no significant differences were found in the histology of the liver, spleen, kidney, brain or tumour from control and thiosemicarbazone treated mice (Figure 8).

[0129] However, myocardial lesions were observed in mice treated with Dp44mT (0.75mg/kg; Figure 8). Such lesions consisted of poorly differentiated foci of necrosis, being replaced with immature fibrous tissue which was obvious using Gomori-Trichrome stain (arrow; Figure 8). However, Dp4e4mT.HCl did not induce myocardial lesions after 3 weeks at 2.5, 5, 7.5 and 10 mg/kg of oral administration (Figure 8).

Example 4c – Effect of Dp4cycH4mT.HCl by i.v Administration on the *in-vivo* Inhibition of PANC 1 Human Pancreatic Carcinoma

[0130] The *in vitro* analysis demonstrated that the thiosemicarbazones Dp44mT and Dp4cycH4mT.HCl are considerably more effective at inhibiting proliferation of a range of pancreatic cancer cell lines when compared to gemcitabine (Figure 3A-C, Tables 2A and B). To further characterize the efficacy of the thiosemicarbazones against pancreatic cancer *in vivo* studies were performed.

[0131] Using PANC 1 xenografts, after 6 weeks of treatment the vehicle control mice had reached an average tumour size of approximately 640% of initial tumour volume while the groups treated with gemcitabine, Dp44mT and Dp4cycH4mT.HCl reached an average of 319%, 305% and 112% of the original tumour size, respectively (Figure 9A). Gemcitabine ($p < 0.01$), Dp44mT ($p < 0.05$) and Dp4cycH4mT.HCl ($p < 0.001$) all significantly reduced tumour volume relative to the control after 43 days of treatment.

[0132] Furthermore, the final tumour weights after 43 days of treatment reflected the tumour volumes with control tumours weighing an average of 292 ± 65 mg while tumours treated with gemcitabine, Dp44mT and Dp4cycH4mT.HCl weighed an average of 67 ± 25 mg, 122 ± 33 mg and 40 ± 12 mg, respectively (Figure 9B). These results show that each treatment was able to significantly inhibit the growth and progression of the tumour xenograft *in vivo*.

[0133] Although the difference between Dp4cycH4mT.HCl and gemcitabine tumour volumes was not statistically significant ($p > 0.05$), the data obtained indicates that after day 32, both gemcitabine and Dp44mT treatments were slightly less effective at inhibiting tumour growth when compared to Dp4cycH4mT.HCl (Figure 9A). As the tumour size of the vehicle control group was the limiting factor in the duration of this experiment, it was not possible to continue further treatment after 43 days due to ethical limitations.

**Example 4c(i) – Biologic Assessment Following i.v. Dp4cycH4mT.HCl Treatment:
Weight loss and Hematological Analyses in Mice Bearing PANC 1 Human Pancreatic
Carcinoma**

[0134] To determine whether the different agents used in the *in vivo* studies above were associated with any toxicity, haematological indices as well as body and organ weights were analyzed following euthanasia.

[0135] Table 7A. Growth of PANC-1 pancreatic carcinoma in nude mice Dp4cycH4mT i.v administration study: Body and organ weights (g).

Organ	Experimental Group (n = 8)		
	Control	Dp4cycH4mT (5 mg/kg/day)	Gemcitabine (5 mg/kg/day)
Body weight loss (% initial weight)	104.9 ± 4.6	88.0 ± 6.5***	104.5 ± 2.2
Liver	0.96 ± 0.11	0.80 ± 0.03	1.04 ± 0.03
Spleen	0.12 ± 0.01	0.08 ± 0.01**	0.13 ± 0.01
Kidney	0.15 ± 0.02	0.17 ± 0.02	0.19 ± 0.03
Heart	0.10 ± 0.01	0.09 ± 0.01	0.10 ± 0.01
Brain	0.32 ± 0.02	0.30 ± 0.01	0.32 ± 0.01
Tumour	0.29 ± 0.07	0.04 ± 0.01***	0.07 ± 0.02**

$p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

[0136] The body weight of the animals after 6 weeks of treatment remained close to 100% of the pre-treatment weight for each group with the exception of Dp4cycH4mT.HCl (Table 7A). These animals showed a significant ($p < 0.001$) weight loss of 12% when compared to their pre-treatment weight (Table 7A). Although no significant differences in the organ weights was found (Table 7A) between the different treatment groups, it was observed that the

Dp4cycH4mT.HCl group also had a significantly ($p < 0.001$) smaller spleen when compared to the control group (Table 7A). A histological analysis of the spleen found that the splenic red pulp of mice in all groups contained a normal population of hematopoietic cells. Therefore, there was no evidence to suggest splenic toxicity (Figure 10).

[0137] Table 7B. Growth of PANC 1 pancreatic carcinoma in nude mice Dp4cycH4mT i.v administration study: Haematology

	Experimental Groups (n=8)		
	Control	Dp4cycH4mT (5 mg/kg/day)	Gemcitabine (5 mg/kg/3days)
RBC x 10 ¹² /L	10.17 ± 0.15	9.46 ± 0.31	9.65 ± 0.08
Hb g/L	146.44 ± 1.68	131.88 ± 4.31**	147.88 ± 1.19
HCT	0.44 ± 0.01	0.41 ± 0.01	0.45 ± 0.01
Platelets 10 ⁹ /L	1042 ± 147	1283 ± 160	1060 ± 205
WBC x 10 ⁹ /L	4.53 ± 0.44	3.5 ± 0.34	5.51 ± 0.56
Reticulocytes x 10 ¹² /L	0.56 ± 0.06	0.77 ± 0.08*	0.35 ± 0.12

$p < 0.05$, ** $p < 0.01$

[0138] Haematological indices, in particular signs of anaemia, was an important parameter to examine as the thiosemicarbazone compounds are iron chelators. No significant difference in the red blood cell (RBC), white blood cell (WBC) or platelet-counts was detected between control and the different treatment groups (Table 7B). However, the Dp44mT and Dp4cycH4mT.HCl groups had significantly ($p < 0.01$) lower haemoglobin (Hb) and significantly ($p < 0.05$) higher reticulocyte levels when compared to the control group (Table 7B). This may be an indicator of a slight anaemia in these animals.

Example 4c(ii) – Effects on Tissue Histology Following Oral Dp4cycH4mT.HCl Treatment in Mice Bearing PANC 1 Human Pancreatic Carcinoma

[0139] To further investigate the potential toxic effects of the different treatments on the organs, a histological analysis of the spleen, kidney, liver, heart, lungs, brain and bone marrow was performed by staining with H&E (for general pathology), Pearls' (for presence of iron) and Gomori-Trichrome (for fibrosis). The histological analysis was performed by a veterinary pathologist and the results are presented in Table 8.

Table 8. Independent histopathological assessment

Treatment Group	BONE	KIDNEY	LIVER	LUNG	MYOCARDIUM		SPLEEN
	HP	Fe	HP	HP	HP	Fibrosis	HPC
Control	N	+	N	N	N	-	N
	N	-	N	N	N	-	N
	N	-	N	N	N	-	N
	N	+	N	N	N	-	N
	N	++	N	N	N	-	N
	N	-	N	N	N	-	N
	N	-	N	N	+/-	-	N
	N	-	N	N	+	-	N
	N	+/-	N	N	N	-	N
Gencitabine	N	-	N	N	N	-	N
	N	-	N	N	N	-	N
	N	-	N	N	N	-	N
	N	-	N	N	N	-	N
	N	-	N	N	N	-	N
	N	-	N	N	N	-	N
	N	-	N	N	N	-	N
Dp44mT	N	++	N	N	++	++	N
	N	+	N	N	+	+	N
	N	++	N	+/-	+	+	N
	N	+	+	N	+	+	N
	N	+	++	+	+	+	N
	N	+	+/-	+/-	+	+	N
	N	+/-	+/-	+	+	+	N
Dp4cycH4mT.HCl	N	+	N	N	N	-	N
	N	+	N	+/-	N	-	N
	N	+	+/-	N	N	-	N
	N	+	+/-	N	N	-	N
	N	+	N	+	N	-	N
	N	+	N	N	N	-	N
	N	+	N	N	N	-	N
	N	+	N	N	N	-	N

HP – Histopathological changes; **Fe** – Score for presence of iron stained by Perl's stain; **HPC** – Score for the presence of haematopoietic cells in the splenic red pulp; **N** – No histopathological changes detected.

(-) No damage; (+/-) Very mild, localized damage; (+) Less than 10% damage; (++) Less than 20% damage.

[0140] Two of the Dp44mT-treated mice contained some evidence of haematopoietic cells in the liver. In addition, iron deposits were observed in the kidneys of 5 of the 10 control-treated mice and all the Dp44mT- and Dp4cycH4mT.HCl-treated animals (Table 8), which may be due to iron in the diet and the excretion of the iron complex formed by the thiosemicarbazone chelators in the urine, respectively. The gemcitabine-treated group had no evidence of iron deposits in the kidney (Table 8). The myocardium of each mouse in the Dp44mT group displayed myocardial lesions that were characterized by myocardial fibre degeneration and necrosis, with replacement by fibrous tissue (Figure 10; Table 8). The pathological changes observed were most pronounced in the wall of the right ventricle and also in the myocardium beneath the endocardium of the left ventricle (Figure 10). This is in agreement with an earlier study that also detected cardio-fibrosis in Dp44mT-treated nude mice. There was no significant evidence of fibrotic lesions in the heart of the Dp4cycH4mT.HCl-treated group, demonstrating that this compound was more potent and far less toxic than Dp44mT *in vivo* at higher doses.

[0141] Significantly, there was no evidence of pathology in any of the other organs examined (Table 8), suggesting that neither Dp4cycH4mT.HCl nor gemcitabine induced marked tissue damage when compared to the untreated controls.

Example 4d: Effect of Dp4cycH4mT on the Expression of the Metastasis Suppressor Protein NDRG-1, Transferrin Receptor and Cell-Cycle Control Molecules.

Methodology:

Western blot analysis

[0142] Protein isolation was performed as described previously (Dunn, L.L., et al (2006) *Carcinogenesis* 27: 2157-69).

[0143] Western analysis was performed *via* established protocols (Gao, J. and D. R. Richardson (2001). *Blood* 98: 842-50). The primary antibodies used were against NDRG1 (Abcam; UK), p21, cyclin D1, transferrin receptor 1 (TfR1; Santa Cruz, CA, USA) and β -actin (Sigma-Aldrich), with secondary HRP-conjugated goat and mouse antibodies (Sigma-Aldrich).

Results:

[0144] Dp4cycH4mT was examined to determine whether it could up-regulate NDRG-1 expression. To further evaluate the effect of the chelator Dp4cycH4mT on other key molecules involved in cell cycle progression, the expression of the cyclin-dependent kinase inhibitor, p21, as well as cyclin D1 in MIAPaCa-2 cells was also examined. As a positive control for iron chelator treatment, transferrin receptor 1 (TfR1) was also examined, as this protein has previously been found to be up-regulated by thiosemicarbazone compounds.

[0145] Both Dp44mT and Dp4cycH4mT significantly ($p < 0.01$) up-regulated NDRG1 expression in MIAPaCa-2 cells, while gemcitabine had no marked effect (Figure 11). In addition, Dp44mT and Dp4cycH4mT also significantly ($p < 0.05$) reduced cyclin D1 levels while markedly ($p < 0.05$) increasing p21 expression in these cells (Figure 11). Moreover, TfR1 levels were also significantly ($p < 0.05$) up-regulated in the MIAPaCa-2 cells following treatment with the thiosemicarbazone compounds, suggesting that these agents were effectively depleting the cells of iron (Figure 11). On the other hand, gemcitabine treatment did not modulate cyclin D1, p21 or TfR1 levels in the MIAPaCa-2 cells (Figure 11), indicating that its mechanism of action is different to that of the thiosemicarbazones.

[0146] Collectively, these results show that NDRG1 is markedly up-regulated by Dp4cycH4mT, suggesting that Dp4cycH4mT may be a beneficial treatment strategy against cancers by targeting NDRG1 expression in cancer cells.

Example 5 : In vitro and in vivo modulation of the levels of methemoglobin (metHb) and metmyoglobin (metMb) by iron chelators

Methodology

Chemicals

[0147] Triapine[®] was synthesized and characterized according to published methods (Liu MC, Lin TC, et al (1992). *J Med Chem* **35**: 3672-3677). Dp44mT, Bp4eT, DpC, di-2-pyridylketone-4-ethyl-4-methyl-3-thiosemicarbazone (Dp4e4mT), di-2-pyridylketone-4-phenyl-3-thiosemicarbazone (Dp4pT) and di-2-pyridylketone-2-methyl-3-thiosemicarbazone (Dp2mT) were also synthesized and characterized using published procedures. Richardson DR, Sharpe PC, et al (2006). *J Med Chem* **49**: 6510-6521; Kalinowski DS, Yu Y, et al, (2007). *J Med Chem* **50**: 3716-3729). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA). For use in the assays described below, compounds were freshly prepared in DMSO and diluted (final [DMSO]<0.05%).

Red blood cell isolation

[0148] Whole blood samples were collected from healthy human donors or mice in suitable blood collection tubes containing EDTA and used immediately. Red blood cells (RBCs) were isolated by centrifugation (480 xg/5 min/4°C) then washed in Hank's balanced salt solution (HBSS). RBCs were resuspended 1:1 in HBSS and whole RBC assays were carried out at 37°C.

Myoglobin preparation

[0149] Mouse heart tissue was exhaustively perfused with ice-cold HBSS to remove blood and homogenized in ice-cold HBSS containing protease inhibitor cocktail (Roche, Basel, Switzerland). Heart homogenates were centrifuged (16,000 xg/45 min/4°C) and the supernatant ([oxyMb]=50 µM) used immediately.

Measurement of methHb and metMb by UV-Vis spectrophotometry

[0150] The levels of methHb and metMb in RBC lysates were determined using a Shimadzu UV-Vis spectrophotometer (UV-1800; Shimadzu Corporation, Kyoto, Japan) at 577 nm and 630 nm for methHb and metMb in accordance with published methods (Winterbourn CC and Carrell RW (1977). *Biochem J* 165: 141-148).

MethHb- and metMb-formation in mice

[0151] C57BL/6 mice (7-8 weeks-old) were used under a protocol approved by the University of Sydney Animal Ethics Committee. Dp44mT, Triapine® or Dp4cycH4mT (all at 6 mg/kg) were dissolved in 30% propylene glycol/saline and administered iv via the tail vein. Subsequently, 30 min after administration, mice were anesthetized with isoflurane and blood samples obtained by cardiac puncture. Blood samples were lysed with 2.5 volumes of ultrapure water for methHb estimation. Mice were sacrificed with isoflurane, the heart exhaustively perfused with HBSS and Mb isolated.

Statistics

[0152] Data were compared using the Student's t-test. Results were considered significant when $p < 0.05$. Results are mean \pm SD.

Example 5a – Ability of iron chelators to induce MethHb-formation in human RBCs

[0153] The effect of chelator concentration (1-25 μ M) on methHb-generation with intact RBCs was assessed (Figure 12). A significant ($p < 0.001$) dose-dependent increase in methHb relative to the control was detected at all ligand concentrations in intact RBCs treated with Triapine® or Dp44mT after 3 h/37°C (Figure 12) which were the only chelators to demonstrate an ability to induce methHb formation. At 25 μ M, these chelators increased methHb formation to 19.95 ± 1.0 and 19.9 ± 3.0 % of total Hb, respectively (Figure 12). The negative control chelator Dp2mT, by design, features a methyl group that hinders complex formation. Accordingly, this chelator cannot participate in the redox-interaction with iron that gives rise to methHb formation (Figure 12). Additionally, the non-redox active chelator DFO, currently used as a treatment for iron overload disorders, also did not increase methHb formation.

[0154] Significantly, Dp4cycH4mT did not potentiate methHb formation in vitro (Figure 12). This may constitute a clear advantage of DpcycH4mT therapy relative to Triapine®.

Example 5b – Ability of the iron chelators Triapine, Dp44mT and Dp4cycH4mT to induce methHb formation in vivo

[0155] To confirm the in vitro results of Example 5a showing that Dp4cycH4mT did not potentiate methHb formation, methHb formation in a mouse model as described above was examined.

[0156] C57BL/6 mice were administered Dp44mT (6 mg/kg), Triapine® (6 mg/kg) or Dp4cycH4mT (6 mg/kg) intravenously and blood taken after 30 min to assess metHb (Figure 13). As previously observed, Dp44mT induced significant ($p < 0.001$) levels of metHb relative to the vehicle (6.3 ± 0.8 compared to $1.3 \pm 0.9\%$ metHb % of total Hb respectively), while metHb levels induced by Dp4cycH4mT were comparable to the control (Figure 13).

[0157] This result with Dp4cycH4mT confirmed the results of the *in vitro* studies in Example 5a and further suggests that Dp4cycH4mT may have the specific advantage of not inducing metHb compared to Dp44mT.

Example 5c – Ability of the iron chelators Triapine, Dp44mT and Dp4cycH4mT to induce metmyoglobin (metMb) formation in vivo

[0158] The protein myoglobin (Mb) plays an important role in oxygen storage and donation to muscles and is a monomeric counterpart to hemoglobin. Accordingly, the effect of potent anticancer active chelators on metMb formation in vivo was assessed. C57BL/6 mice were administered Dp44mT (6 mg/kg), Triapine® (6 mg/kg) or Dp4cycH4mT (6 mg/kg) intravenously and blood taken after 30 min to assess metMb (Figure 14).


[0159] The chelator Dp44mT induced significant ($p < 0.001$) levels of metMb ($82.3 \pm 2.6\%$) which was similar to that of Triapine® ($75.2 \pm 4.2\%$), whereas Dp4cycH4mT generated significantly ($p < 0.001$) lower levels of metMb ($31.7 \pm 3.2\%$; Figure 14).

[0160] However, Dp4cycH4mT-mediated levels of metMb were significantly ($p < 0.001$) higher than the control ($12.6 \pm 2.4\%$; Figure 14).

[0161] Collectively, the properties of Dp4cycH4mT, in terms of being significantly less effective at inducing metHb- and metMb-formation, while maintaining anti-tumor activity (Kovacevic Z, Chikhani S, et al., (2011). *Mol Pharm* 80: 598-609) suggest that Dp4cycH4mT has significant advantages over Triapine® and Dp44mT.

Claims:

1. A compound of general formula (I):




wherein R¹ is cyclohexyl or ethyl;

and salts, hydrates and solvates thereof.


2. The compound according to claim 1, which is di-2-pyridylketone 4-ethyl-4-methyl-3-thiosemicarbazone, and salts, hydrates and solvates thereof.
3. The compound according to claim 1, which is di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone, and salts, hydrates and solvates thereof.
4. The compound according to any one of claims 1 to 3, wherein the salts are pharmaceutically acceptable salts.
5. The compound according to claim 2, which is di-2-pyridylketone 4-ethyl-4-methyl-3-thiosemicarbazone hydrochloride.
6. The compound according to claim 3, which is di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone hydrochloride.
7. A pharmaceutical composition comprising a compound of formula (I), or a salt, hydrate or solvate thereof according to any one of claims 1 to 6, together with a pharmaceutically acceptable excipient, diluent or adjuvant.
8. A method of treating cancer in a mammal, the method comprising administering to a mammal in need thereof an effective amount of a compound of formula (I), or a salt, hydrate or solvate thereof according to any one of claims 1 to 6, or a pharmaceutical composition according to claim 7.

9. The method according to claim 8, wherein the cancer is selected from melanoma, skin cancer, breast cancer, prostate cancer, bladder cancer, liver cancer, gastrointestinal cancer, colon and rectal cancer, brain cancer, head and neck cancer, bone cancer, pancreatic cancer, uterine cancer, ovarian cancer, cervical cancer, lung cancer and haematological tumours (eg, leukaemias and lymphomas).
10. The method according to claim 8 or 9, wherein the cancer is selected from pancreatic cancer, lung cancer and brain cancer.
11. The method according to claim 8, wherein the cancer is a solid tumour.
12. The method according to any one of claims 8 to 11, wherein the mammal is a human.
13. Use of a compound of formula (I) or a salt, hydrate or solvate thereof according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment of cancer.
14. The use according to claim 13, wherein the cancer is selected from melanoma, skin cancer, breast cancer, prostate cancer, bladder cancer, liver cancer, gastrointestinal cancer, colon and rectal cancer, brain cancer, head and neck cancer, bone cancer, pancreatic cancer, uterine cancer, ovarian cancer, cervical cancer, lung cancer and haematological tumours (eg, leukaemias and lymphomas).
15. The use according to claim 14, wherein the cancer is selected from pancreatic cancer, lung cancer and brain cancer.
16. The use according to claim 14, wherein the cancer is a solid tumour.
17. A compound of formula (I) or a salt, hydrate or solvate thereof according to any one of claims 1 to 6 for use in the treatment of cancer.

A



Dp4e4mT



Dp4cycH4mT

B




Figure 1




Figure 2





Figure 3

A



B




Figure 4





Figure 5

6/14




Controls



Dp4e4mT-HCl
1.5 mg



Dp4e4mT-HCl
4 mg



Dp4e4mT-HCl
6 mg




Dp44mT
0.75 mg

Figure 6

7/14

A



B




Figure 7






Figure 8



C



Figure 9





Figure 10

A



B




Figure 11

12/14




Figure 12




Figure 13




Figure 14

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2011/001631

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl.		
C07D 213/53 (2006.01) A61K 31/444 (2006.01) A61P 35/00 (2006.01)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
STN file Registry, CAPLUS		
Structure search encompassing the compounds of claim 1		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2004/069801 A1 (UNISEARCH LIMITED), 19 August 2004 See abstract; Figure 2; Claims 15, 18, 26 and 27;	1-17
X	CN 1891701 A (SANGDIYA PHARMACEUTICAL TECHNOLOGY SHAGHAI CLC), 10 January 2007 See compound S00178, page 15 & CAPLUS accession number 2007:44838	1-17
A	DE 42 07 400 A1 (BAYER AG), 16 September 1993 See compound 102, page 18; Compounds 175-177, page 22; Compounds 205 and 206, page 23; Abstract	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family	
"P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 08 February 2012	Date of mailing of the international search report 21 FEBRUARY 2012	
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. +61 2 6283 7999	Authorized officer ANDREW BRYCE AUSTRALIAN PATENT OFFICE (ISO 9001 Quality Certified Service) Telephone No : +61 2 6283 3132	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2011/001631

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Kovacevic Z. <i>et al.</i> "Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity" <i>Current Drug Delivery</i> (2010), vol. 7, pages 194-207 See Figure 3; Page 199, right-hand column, last paragraph to page 201, right-hand column, second paragraph</p>	
A	<p>Richardson D.R. <i>et al.</i> "Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents" <i>Biochimica et Biophysica Acta</i> (2009), vol. 1790, no. 7, pages 702-17 See Figure 5, page 711</p>	
A	<p>Whitnall M. <i>et al.</i> "A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics" <i>Proceedings of the National Academy of Sciences USA</i> (2006), vol. 103, no. 40, pages 14901-14906 See Figure 1B, compounds DpT, Dp4aT, Dp4eT, Dp44mT, Dp4mT and Dp4pT</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU2011/001631

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
WO	2004/069801	AU	2004210010	CA	2515027	CN	1764644
		EP	1608623	JP	2006516979	US	2006252798
CN	1891701	NONE					
DE	42 07 400	NONE					
Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.							
END OF ANNEX							